Last reviewed · How we verify
Austrian CoronaVirus Adaptive Clinical Trial (COVID-19) (ACOVACT)
The Austrian Coronavirus Adaptive Clinical Trial (ACOVACT) is a randomized, controlled, multicenter, open-label basket trial that aims to compare various antiviral treatments for COVID-19. Moreover three substudies have been integrated. Currently, patients will be randomized to receive (hydroxy-)chloroquine (Treatment stopped after reports of safety issues), lopinavir/ritonavir, remdesivir or standard of care. Moreover, these patients are eligible for substudy A (randomized to rivaroxaban 5mg 1-0-1 vs. standard of care), substudy B (renin-angiotensin (RAS) blockade vs. no RAS blockade for patients with blood pressure \>120/80mmHg), and substudy C (asunercept vs standard of care, pentglobin vs. standard of care for patients with respiratory deterioration and high inflammatory biomarkers). Endpoints were chosen based on the master protocol published by the World Health Organisation and include a 7-point scale of clinical performance, mortality, oxygen requirement (both dose and type), duration of hospitalization, viral load and safety.
Details
| Lead sponsor | Medical University of Vienna |
|---|---|
| Phase | PHASE2, PHASE3 |
| Status | UNKNOWN |
| Enrolment | 500 |
| Start date | Thu Apr 16 2020 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Thu Mar 31 2022 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- COVID-19
Interventions
- Chloroquine or Hydroxychloroquine
- Lopinavir/Ritonavir
- Best standard of care
- Rivaroxaban
- Thromboprophylaxis
- Candesartan
- non-RAS blocking antihypertensives
- Remdesivir
- Asunercept 400mg
- Asunercept 100mg
Countries
Austria